226 related articles for article (PubMed ID: 19557894)
1. Pharmacoeconomic evaluations of antifungal therapies.
Hennen CR
Curr Med Res Opin; 2009 Jul; 25(7):1751-8. PubMed ID: 19557894
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
Slavin MA; Szer J; Grigg AP; Roberts AW; Seymour JF; Sasadeusz J; Thursky K; Chen SC; Morrissey CO; Heath CH; Sorrell T
Intern Med J; 2004 Apr; 34(4):192-200. PubMed ID: 15086700
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.
Johnson MD; Kleinberg M; Danziger L; Ostrosky-Zeichner L
Expert Opin Pharmacother; 2005 Dec; 6(15):2617-32. PubMed ID: 16316301
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.
Moeremans K; Annemans L
Expert Opin Pharmacother; 2006 Oct; 7(14):1931-43. PubMed ID: 17020419
[TBL] [Abstract][Full Text] [Related]
6. Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives.
Neoh CF; Slavin M; Chen SC; Stewart K; Kong DC
Int J Antimicrob Agents; 2014 Mar; 43(3):207-14. PubMed ID: 24670423
[TBL] [Abstract][Full Text] [Related]
7. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs.
Swoboda S; Lichtenstern C; Ober MC; Taylor LA; Störzinger D; Michel A; Brobeil A; Mieth M; Hofer S; Sonntag HG; Hoppe-Tichy T; Weigand MA
Chemotherapy; 2009; 55(6):418-24. PubMed ID: 19996586
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis.
Frankum LE; Nightengale B; Russo CL; Sarnes M
Manag Care Interface; 2005 Jan; 18(1):55-63. PubMed ID: 15682633
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.
Turner SJ; Chen SC; Slavin MA; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):227-35. PubMed ID: 23570433
[TBL] [Abstract][Full Text] [Related]
10. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
11. New antifungal agents in pediatric practice.
Das S; Shivaprakash MR; Chakrabarti A
Indian Pediatr; 2009 Mar; 46(3):225-31. PubMed ID: 19346570
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomics--an aid to better decision-making.
Arenas-Guzman R; Tosti A; Hay R; Haneke E;
J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
[TBL] [Abstract][Full Text] [Related]
13. Selected topical antifungal use in managed care.
Rich SJ; Grudzinski AN
Med Interface; 1996 Oct; 9(10):80-2. PubMed ID: 10161515
[TBL] [Abstract][Full Text] [Related]
14. Selection criteria for antifungals: the right patients and the right reasons.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():17-20. PubMed ID: 16707246
[TBL] [Abstract][Full Text] [Related]
15. Reply: Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
Huprikar S
Liver Transpl; 2008 May; 14(5):709. PubMed ID: 18433053
[No Abstract] [Full Text] [Related]
16. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
; Böhme A; Ruhnke M; Buchheidt D; Cornely OA; Einsele H; Enzensberger R; Hebart H; Heinz W; Junghanss C; Karthaus M; Krüger W; Krug U; Kubin T; Penack O; Reichert D; Reuter S; Silling G; Südhoff T; Ullmann AJ; Maschmeyer G
Ann Hematol; 2009 Feb; 88(2):97-110. PubMed ID: 18853161
[TBL] [Abstract][Full Text] [Related]
17. The case for antifungal stewardship.
Ananda-Rajah MR; Slavin MA; Thursky KT
Curr Opin Infect Dis; 2012 Feb; 25(1):107-15. PubMed ID: 22123667
[TBL] [Abstract][Full Text] [Related]
18. Fungal infections and their treatment in the intensive care unit.
Sarosi GA
Curr Opin Crit Care; 2006 Oct; 12(5):464-9. PubMed ID: 16943727
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
Dixon S; McKeen E; Tabberer M; Paisley S
Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
[TBL] [Abstract][Full Text] [Related]
20. Economic issues with new rheumatologic therapeutics.
Kavanaugh A
Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
